The HIV-1 envelope (Env) glycans shield the surface of Env from the immune system and form integral interactions important for a functional Env. To understand how individual N-glycosylation sites (NGS) coordinate to form a dynamic shield and evade the immune system through mutations, we tracked 20 NGS in Env from HIV-transmitted/founder (T/F) and immune escape variants and their mutants involving the N262 glycan. NGS were profiled in a site-specific manner using a high-resolution mass spectrometry (MS)-based workflow. Using this site-specific quantitative heterogeneity profiling, we empirically characterized the interdependent NGS of a microdomain in the high-mannose patch (HMP). The changes (shifts) in NGS heterogeneity between the T/F and immune escape variants defined a range of NGS that we further probed for exclusive combinations of sequons in the HMP microdomain using the Los Alamos National Laboratory HIV sequence database. The resultant sequon combinations, including the highly conserved NGS N262, N448, and N301, created an immune escape map of the conserved and variable sequons in the HMP microdomain. This report provides details on how some clustered NGS form microdomains that can be identified and tracked across Env variants. These microdomains have a limited number of N-glycan-sequon combinations that may allow the anticipation of immune escape variants.IMPORTANCE The Env protein of HIV is highly glycosylated, and the sites of glycosylation can change as the virus mutates during immune evasion. Due to these changes, the glycan location and heterogeneity of surrounding N-glycosylation sites can be altered, resulting in exposure of different glycan or proteoglycan surfaces while still producing a viable HIV variant. These changes present a need for vaccine developers to identify Env variants with epitopes most likely to induce durable protective responses. Here we describe a means of anticipating HIV-1 immune evasion by dividing Env into N-glycan microdomains that have a limited number of N-glycan sequon combinations.

Department of Biochemistry and Molecular Genetics University of Alabama at Birmingham Birmingham Alabama USA

Department of Immunology and Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czech Republic

Department of Microbiology University of Alabama at Birmingham Birmingham Alabama USA

Optys Tech Corporation Shrewsbury Massachusetts USA

Zobrazit více v PubMed

Stewart-Jones GB, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, Thomas PV, Wagh K, Zhou T, Behrens AJ, Bylund T, Choi CW, Davison JR, Georgiev IS, Joyce MG, Kwon YD, Pancera M, Taft J, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CC, Wu CY, Bewley CA, Burton DR, Koff WC, Connors M, Crispin M, Baxa U, Korber BT, Wong CH, Mascola JR, Kwong PD. 2016. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165:813–826. doi:10.1016/j.cell.2016.04.010. PubMed DOI PMC

Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884–1888. doi:10.1126/science.280.5371.1884. PubMed DOI

Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, Rosen CA, Haseltine WA, Lee TH, Essex M. 1985. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091–1094. doi:10.1126/science.2986290. PubMed DOI

Medina-Ramirez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof T, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW. 2017. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med 214:2573–2590. doi:10.1084/jem.20161160. PubMed DOI PMC

Cheng C, Pancera M, Bossert A, Schmidt SD, Chen RE, Chen X, Druz A, Narpala S, Doria-Rose NA, McDermott AB, Kwong PD, Mascola JR. 2015. Immunogenicity of a prefusion HIV-1 envelope trimer in complex with a quaternary-structure-specific antibody. J Virol 90:2740–2755. doi:10.1128/JVI.02380-15. PubMed DOI PMC

Kong L, Torrents de la Pena A, Deller MC, Garces F, Sliepen K, Hua Y, Stanfield RL, Sanders RW, Wilson IA. 2015. Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta Crystallogr D Biol Crystallogr 71:2099–2108. doi:10.1107/S1399004715013917. PubMed DOI PMC

Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park SR, Sok D, Su CY, Delahunty CM, Menis S, Andrabi R, Guenaga J, Georgeson E, Kubitz M, Adachi Y, Burton DR, Schief WR, Yates Iii JR, Paulson JC. 2017. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nat Commun 8:14954. doi:10.1038/ncomms14954. PubMed DOI PMC

Panico M, Bouche L, Binet D, O'Connor MJ, Rahman D, Pang PC, Canis K, North SJ, Desrosiers RC, Chertova E, Keele BF, Bess JW Jr, Lifson JD, Haslam SM, Dell A, Morris HR. 2016. Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding. Sci Rep 6:32956. doi:10.1038/srep32956. PubMed DOI PMC

Go EP, Chang Q, Liao HX, Sutherland LL, Alam SM, Haynes BF, Desaire H. 2009. Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res 8:4231–4242. doi:10.1021/pr9002728. PubMed DOI PMC

Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, Druz A, Geng H, McKee K, Kwon YD, O'Dell S, Sastry M, Schmidt SD, Xu K, Chen L, Chen RE, Louder MK, Pancera M, Wanninger TG, Zhang B, Zheng A, Farney SK, Foulds KE, Georgiev IS, Joyce MG, Lemmin T, Narpala S, Rawi R, Soto C, Todd JP, Shen CH, Tsybovsky Y, Yang Y, Zhao P, Haynes BF, Stamatatos L, Tiemeyer M, Wells L, Scorpio DG, Shapiro L, McDermott AB, Mascola JR, Kwong PD. 2017. Quantification of the impact of the HIV-1-glycan shield on antibody elicitation. Cell Rep 19:719–732. doi:10.1016/j.celrep.2017.04.013. PubMed DOI PMC

Behrens AJ, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M. 2017. Molecular architecture of the cleavage-dependent mannose patch on a soluble HIV-1 envelope glycoprotein trimer. J Virol 91:e01894-16. doi:10.1128/JVI.01894-16. PubMed DOI PMC

Pritchard LK, Spencer DI, Royle L, Bonomelli C, Seabright GE, Behrens AJ, Kulp DW, Menis S, Krumm SA, Dunlop DC, Crispin DJ, Bowden TA, Scanlan CN, Ward AB, Schief WR, Doores KJ, Crispin M. 2015. Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6:7479. doi:10.1038/ncomms8479. PubMed DOI PMC

Andrabi R, Su CY, Liang CH, Shivatare SS, Briney B, Voss JE, Nawazi SK, Wu CY, Wong CH, Burton DR. 2017. Glycans function as anchors for antibodies and help drive HIV broadly neutralizing antibody development. Immunity 47:1004. doi:10.1016/j.immuni.2017.10.012. PubMed DOI PMC

Lee JH, Ozorowski G, Ward AB. 2016. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351:1043–1048. doi:10.1126/science.aad2450. PubMed DOI PMC

Lemmin T, Soto C, Stuckey J, Kwong PD. 2017. Microsecond dynamics and network analysis of the HIV-1 SOSIP Env trimer reveal collective behavior and conserved microdomains of the glycan shield. Structure 25:1631–1639.e2. doi:10.1016/j.str.2017.07.018. PubMed DOI

Kong L, Wilson IA, Kwong PD. 2015. Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262. Proteins 83:590–596. doi:10.1002/prot.24747. PubMed DOI PMC

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E, IAVI Protocol C Investigators, IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P. 2017. HIV envelope glycoform heterogeneity and localized diversity govern the initiation and maturation of a V2 apex broadly neutralizing antibody lineage. Immunity 47:990–1003.e9. doi:10.1016/j.immuni.2017.11.002. PubMed DOI PMC

Preston BD, Poiesz BJ, Loeb LA. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168–1171. doi:10.1126/science.2460924. PubMed DOI

Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307–312. doi:10.1038/nature01470. PubMed DOI

Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S, Chen XS, Wang Y. 2013. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology 10:14. doi:10.1186/1742-4690-10-14. PubMed DOI PMC

Mathys L, Francois KO, Quandte M, Braakman I, Balzarini J. 2014. Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. PLoS One 9:e101181. doi:10.1371/journal.pone.0101181. PubMed DOI PMC

Go EP, Hewawasam G, Liao HX, Chen H, Ping LH, Anderson JA, Hua DC, Haynes BF, Desaire H. 2011. Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85:8270–8284. doi:10.1128/JVI.05053-11. PubMed DOI PMC

Behrens AJ, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, Struwe WB, Cupo A, Kumar A, Zitzmann N, Seabright GE, Kramer HB, Spencer DI, Royle L, Lee JH, Klasse PJ, Burton DR, Wilson IA, Ward AB, Sanders RW, Moore JP, Doores KJ, Crispin M. 2016. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Rep 14:2695–2706. doi:10.1016/j.celrep.2016.02.058. PubMed DOI PMC

Raska M, Takahashi K, Czernekova L, Zachova K, Hall S, Moldoveanu Z, Elliott MC, Wilson L, Brown R, Jancova D, Barnes S, Vrbkova J, Tomana M, Smith PD, Mestecky J, Renfrow MB, Novak J. 2010. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285:20860–20869. doi:10.1074/jbc.M109.085472. PubMed DOI PMC

Rebecchi KR, Wenke JL, Go EP, Desaire H. 2009. Label-free quantitation: a new glycoproteomics approach. J Am Soc Mass Spectrom 20:1048–1059. doi:10.1016/j.jasms.2009.01.013. PubMed DOI

Takahashi K, Wall SB, Suzuki H, Smith ADt, Hall S, Poulsen K, Kilian M, Mobley JA, Julian BA, Mestecky J, Novak J, Renfrow MB. 2010. Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation. Mol Cell Proteomics 9:2545–2557. doi:10.1074/mcp.M110.001834. PubMed DOI PMC

Zhang X, Wang Y. 2016. Glycosylation quality control by the Golgi structure. J Mol Biol 428:3183–3193. doi:10.1016/j.jmb.2016.02.030. PubMed DOI PMC

Hargett A, Wei Q, Raksa M, Knoppona B, Hall S, Zachova K, Huang Z, Moldoveanu Z, Novak J, Renfrow MB. 2015. Glycosylation patterns on HIV-1 envelope glycoprotein. Glycobiology 25:1249.

Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD. 2013. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20:804–813. doi:10.1038/nsmb.2600. PubMed DOI PMC

Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065–2071. doi:10.1126/science.1083182. PubMed DOI

Behrens AJ, Crispin M. 2017. Structural principles controlling HIV envelope glycosylation. Curr Opin Struct Biol 44:125–133. doi:10.1016/j.sbi.2017.03.008. PubMed DOI PMC

Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien JP, Menis S, Wickramasinghe L, Seaman MS, Schief WR, Wilson IA, Poignard P, Burton DR. 2014. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6:236ra63. doi:10.1126/scitranslmed.3008104. PubMed DOI PMC

Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, Burton DR. 2015. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J Virol 89:1105–1118. doi:10.1128/JVI.02905-14. PubMed DOI PMC

Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C. 2017. Cooperation between strain-specific and broadly neutralizing responses limited viral escape and prolonged the exposure of the broadly neutralizing epitope. J Virol 91:e00828-17. doi:10.1128/JVI.00828-17. PubMed DOI PMC

Fujimoto A, Okada Y, Boroevich KA, Tsunoda T, Taniguchi H, Nakagawa H. 2016. Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes. Sci Rep 6:26483. doi:10.1038/srep26483. PubMed DOI PMC

Go EP, Ding H, Zhang S, Ringe RP, Nicely N, Hua D, Steinbock RT, Golabek M, Alin J, Alam SM, Cupo A, Haynes BF, Kappes JC, Moore JP, Sodroski JG, Desaire H. 2017. Glycosylation benchmark profile for HIV-1 envelope glycoprotein production based on eleven Env trimers. J Virol 91:e02428-16. doi:10.1128/JVI.02428-16. PubMed DOI PMC

Struwe WB, Chertova E, Allen JD, Seabright GE, Watanabe Y, Harvey DJ, Medina-Ramirez M, Roser JD, Smith R, Westcott D, Keele BF, Bess JW Jr, Sanders RW, Lifson JD, Moore JP, Crispin M. 2018. Site-specific glycosylation of virion-derived HIV-1 Env is mimicked by a soluble trimeric immunogen. Cell Rep 24:1958–1966.e5. doi:10.1016/j.celrep.2018.07.080. PubMed DOI PMC

Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, Schmidt SD, Mankoff Z, Wu L, Asokan M, Beil C, Lange C, Leuschner WD, Kruip J, Sendak R, Do Kwon Y, Zhou T, Chen X, Bailer RT, Wang K, Choe M, Tartaglia LJ, Barouch DH, O’Dell S, Todd JP, Burton DR, Roederer M, Connors M, Koup RA, Kwong PD, Yang ZY, Mascola JR, Nabel GJ. 2017. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358:85–90. doi:10.1126/science.aan8630. PubMed DOI PMC

Ozorowski G, Pallesen J, de Val N, Lyumkis D, Cottrell CA, Torres JL, Copps J, Stanfield RL, Cupo A, Pugach P, Moore JP, Wilson IA, Ward AB. 2017. Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Nature 547:360–363. doi:10.1038/nature23010. PubMed DOI PMC

Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105:7552–7557. doi:10.1073/pnas.0802203105. PubMed DOI PMC

Raska M, Czernekova L, Moldoveanu Z, Zachova K, Elliott MC, Novak Z, Hall S, Hoelscher M, Maboko L, Brown R, Smith PD, Mestecky J, Novak J. 2014. Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection. AIDS Res Ther 11:23. doi:10.1186/1742-6405-11-23. PubMed DOI PMC

Raska M, Moldoveanu Z, Novak J, Hel Z, Novak L, Bozja J, Compans RW, Yang C, Mestecky J. 2008. Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. Vaccine 26:1541–1551. doi:10.1016/j.vaccine.2008.01.035. PubMed DOI PMC

Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao H, Todd CA, Ozaki DA, Seaman MS, Mascola JR, Montefiori DC. 2014. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 409:131–146. doi:10.1016/j.jim.2013.11.022. PubMed DOI PMC

Schachter H. 2000. The joys of HexNAc. The synthesis and function of N- and O-glycan branches. Glycoconj J 17:465–483. doi:10.1023/A:1011010206774. PubMed DOI

Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195–201. doi:10.1093/bioinformatics/bti770. PubMed DOI

Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486–501. doi:10.1107/S0907444910007493. PubMed DOI PMC

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

Quantitative assessment of successive carbohydrate additions to the clustered O-glycosylation sites of IgA1 by glycosyltransferases

Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies

Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice